InsidersTradesSigma
Track the Diamyd Medical AB stock price and the full insider trade history of the company, a listed issuer based in Finland. Shares are listed on the FI market, under the oversight of FIN-FSA. Operating in the Health Care sector, Diamyd Medical AB has published 7 reports. Market capitalisation: €159.9m. The latest transaction was disclosed on 24 June 2026 (Purchase). Among the most active insiders: Anders Essen-Möller. All data is free.
7
Insider Decl.
n/a
Thresholds
€596,975
7 ops.
Buy Volume
n/a
n/a
Sell Volume
47Σ signal
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 24 June 2026
Declarations7 total
100,000 shares@ SEK 1.000.0059% mcap1.6% of flowAktieISIN SE0005162880FI:csv-c0583c028b9c2148656e
200,000 shares@ €0.09670.012% mcap100.0% of flowAktieISIN SE0020997468FI:A003X890-1
1,000 shares@ €0.90490.0005% mcap100.0% of flowBTU (betald tecknad unit)ISIN SE0024467914FI:A003N869-1
1,020 shares@ €0.72770.0004% mcap100.0% of flowBTU (betald tecknad unit)ISIN SE0024467914FI:A003N791-1
327,124 shares@ €0.73150.14% mcap42.9% of flowBTU (betald tecknad unit)ISIN SE0022760336FI:A003N796-1
435,630 shares@ €0.73150.19% mcap57.1% of flowBTU (betald tecknad unit)ISIN SE0005162880FI:A003N795-1
12,500 shares@ €0.72770.0055% mcap100.0% of flowBTU (betald tecknad unit)ISIN SE0024467914FI:A003N704-1
7 of 7 declarations
About Diamyd Medical AB
Diamyd Medical AB is a Swedish biopharmaceutical company focused on developing treatments for type 1 diabetes. The company specializes in innovative therapies based on recombinant proteins.